Lower disease severity associated with better quality of life in dermatitis
MILAN — Atopic dermatitis patients with lower disease severity and better quality of life also were associated with lower clinical burdens and work impairment, according to a poster presented at the European Academy of Dermatology and Venereology Congress.
“Atopic dermatitis (AD) is a multidimensional, chronic, relapsing, inflammatory skin disease that can cause severe skin symptoms and intense pruritus that greatly affect patients’ quality of life (QOL),” Melinda J. Gooderham, MD, of the Skin Centre for Dermatology at Queens University in Peterborough, Ontario, Canada, and colleagues wrote.
Atopic dermatitis patients with lower disease severity and better quality of life also were associated with lower clinical burdens and work impairment.
This analysis of data from the cross-sectional, 28-country MEASURE-AD study included 1,434 adult patients with AD.
Patient-reported QOL, as measured by the DLQI, was used to stratify patients into four groups: no effect (0-1) or small effect (2-5); moderate effect (6-10); very large effect (11-20); and extremely large effect (21-30).
Disease severity was measured using the Patient-Oriented Eczema Measure categories of clear or almost clear, mild, moderate, severe and very severe.
Patients with better DLQI and POEM scores also had lower EASI and Worst Pruritus Numeric Rating Scale scores, the study found.
In addition, work productivity impairment was lower in patients with less severe patient-reported outcomes.
“Results from MEASURE-AD broaden awareness of the continued burden that people living with atopic dermatitis experience every day and of the potential link between disease severity, treatment approach and overall impact on patient-reported quality of life,” Juan Francisco Silvestre, MD, attending dermatologist at the General University Hospital of Alicante in Alicante, Spain, and investigator for the MEASURE-AD study, said in a press release. “These real-world analyses underscore the multidimensional burden of atopic dermatitis and the need for more therapeutic options for patients.”
Reference:
- New MEASURE-AD analyses evaluate clinical, psychosocial and economic burdens in atopic dermatitis patients. https://news.abbvie.com/news/press-releases/new-measure-ad-analyses-evaluate-clinical-psychosocial-and-economic-burdens-in-atopic-dermatitis-patients.htm. Published Sept. 8, 2022. Accessed Sept. 8, 2022.